8/10/2019 Agila Brochure

1/12

Mylan.com NON-2013-0059

Agila isnow aMylan

company

8/10/2019 Agila Brochure

2/12

Who is Mylan?Were one of the worlds largest

generic and specialty pharmaceutical

companies, providing essential

medicine to people around the globe.

Were experts in making difficult to

manufacture medicine and therapies.

Today, our portfolio includes1,264

approved products and 965pending

global approvals.* Now, with Agila,

well be able to offer even more medicine

to even more people.

*The above numbers provide country-level submission details only.

As of July 30, 2013.

8/10/2019 Agila Brochure

3/12

For more than

50 years, oneclear mission.With the addition of Agilas broad portfolio

of existing injectable products, pipeline,

technology and manufacturing, Mylan

advances its mission to provide 7 billionpeople access to high quality medicine.

Because, when you get right down to it,

we know where our priorities areit all

starts and ends with you.

8/10/2019 Agila Brochure

4/12

Quality

Manufacturing

Products

Reliability

Innovation

Access

What this acquisition

means to you.

8/10/2019 Agila Brochure

5/12

Quality

Mylan is

committed tosetting thebar for quality.Worldwide.

With Agila, Mylan can extend its reputationfor uncompromising quality in the areas

of injectables, infrastructure, capabilities

and manufacturing across all product lines.

Because at Mylan our priorities are to meet

or exceed industry standards,we apply

one global quality standard across our

facilities, and across our product linesregardless of market.

Our goal is to create and provide access

to dependable, consistent, high quality

products, whether you get them around

the corner or around the world.

8/10/2019 Agila Brochure

6/12

Manufacturing

An even greater

emphasis onmanufacturing.With Agila, Mylan brings an even broader

approach to the injectables market.

Diversity.Expanded focus on important

therapeutic categories brings you morehigh-quality products in more diverse forms

than ever before

Capacity.A stronger global presence that

will nearly doubleour injectables production

from ~350M units to ~650Munits by

2016 to better respond to your needs

Capability.Increased technologicalcapabilitiesbuild upon industry-leading

sterile manufacturing, enhanced

lyophilization processes, advanced

delivery systems, and facilities dedicated

to -lactams and penems

8/10/2019 Agila Brochure

7/12

Products

A wider range

of productswith a focus onkey therapies.By acquiring Agila, Mylan now commands

one of the largest injectables portfolios

in the industrywhich will benefit morepeople around the world.

Now Mylan has:

A leadership role in oncology

Expanded focus on essential therapies,

like anti-infectivesand cardiovascular

treatments

Expanded manufacturing infrastructureand capabilities

Accelerated the ability to pursue new

product opportunities

Created a broader range of therapeutic

areas

8/10/2019 Agila Brochure

8/12

Reliability

Count on us.

Around the world.The acquisition of Agila complements Mylans

reputation as a reliable global supplier of

important high quality medicine, services

and supply.

Because Mylan can leverage the capabilities

and resources of 9 new injectables

facilities, and a significantly more

vertically-integrated product portfolio.

8/10/2019 Agila Brochure

9/12

Innovation

If theres a

better way,Mylan iscommitted tofinding it.

With the addition of Agila, Mylan canexpand delivery of innovative solutions

including advanced delivery systems

and efficienciesand better respond

to customer needs while maintaining

sound manufacturing practices.

Because our resources in injectables

include more than 400 dedicatedscientists and 4 R&D facilities,

all performing under one consistent

global quality standard.

8/10/2019 Agila Brochure

10/12

Access

Its all about

helping as manypeople as possible.With the Agila acquisition, Mylan is better

positioned to bring high quality injectable

medicine to more people in more places

than ever before.

Because Mylans proven manufacturing

standards and enhanced infrastructure and

capabilitiesare already in place, helping to

give people worldwide access to essential

medicines and therapies.

8/10/2019 Agila Brochure

11/12

The Mylan

mission continuesThis is just the beginning of an exciting

new chapter for Mylan and our customers

and partners.

With enhancedresources, an expanded

product line, and our ability to fulfill our

commitment to global quality, it opens

up brand new ways to further our mission

to bring important medicine to more

than 7 billion people around the world.

8/10/2019 Agila Brochure

12/12

At Mylan, we

are committedto setting newstandards inhealth care.

Working together around the world toprovide 7 billion people access to high

quality medicine, we:

Innovate to satisfy unmet needs

Make reliability and service excellence

a habit

Do whats right, not whats easy

Impact the future through passionate

global leadership

Mylan.com